Diabetes medication Humalog faces shortage in Canada – National | 24CA News
Eli Lilly, a significant U.S.-based drugmaker, has issued a warning concerning a scarcity of insulin treatment in Canada, which is anticipated to persist by means of mid-April.
The 10-millilitre vials of the insulin Humalog are impacted by the scarcity, Drug Shortages Canada first reported on Monday.
Humalog, also called insulin lispro, is a “fast-acting” insulin used to manage excessive blood sugar in adults and youngsters with Type 1 or Type 2 diabetes, in line with Eli Lilly’s web site.
“Lilly Canada has posted a shortage of the Humalog 10 mL vial on Drug Shortages Canada,” an Eli Lilly spokesperson advised Global News in a Friday electronic mail. “Lilly is currently managing the existing Canadian supply of the 10 mL vial to ensure minimal disruption at the patient level.”
The insulin scarcity is anticipated to be resolved on April 14 “with intermittent cycles of product replenishment in the coming months and we will continue to manage supply to minimize any disruption for patients,” the spokesperson added.
Drug Shortages Canada stated the scarcity is because of a delay in delivery of the drug.
Eli Lilly has additionally posted a scarcity of the treatment within the United States.
The scarcity solely impacts the vial format of the insulin. Eli Lilly stated the Humalog treatment can also be accessible in cartridges and pre-filled multi-dose pens (KwikPen) and there “may be alternative formals of the insulin for patients and health-care professionals to consider, where appropriate.”
“For patients requiring a vial only, a biosimilar option of Humalog is available and currently not reporting any shortages,” the corporate acknowledged.
© 2024 Global News, a division of Corus Entertainment Inc.
